POINT Biopharma Global Inc. – NASDAQ:PNT
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
POINT Biopharma Global stock price monthly change
-9.16%
month
POINT Biopharma Global stock price quarterly change
+83.28%
quarter
POINT Biopharma Global stock price yearly change
+81.42%
year
POINT Biopharma Global key metrics
Market Cap | 1.33B |
Enterprise value | N/A |
P/E | 6.85 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 1.1 |
Revenue | 243.69M |
EBITDA | 93.90M |
Income | 96.55M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 43.36% |
Oper. margin | 55.38% |
Gross margin | 0% |
EBIT margin | 55.38% |
EBITDA margin | 38.54% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePOINT Biopharma Global stock price history
POINT Biopharma Global stock forecast
POINT Biopharma Global financial statements
| Dec 2022 | 226.57M | 163.26M | 72.06% |
|---|---|---|---|
| Mar 2023 | 9.45M | -16.53M | -174.79% |
| Jun 2023 | 4.86M | -25.41M | -522.23% |
| Sep 2023 | 2.78M | -24.77M | -887.97% |
| 2025 | 218.98M | 37.41M | 17.08% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 578322736 | 91.36M | 15.8% |
|---|---|---|---|
| Mar 2023 | 558524209 | 86.74M | 15.53% |
| Jun 2023 | 497774772 | 50.32M | 10.11% |
| Sep 2023 | 477704420 | 53.51M | 11.2% |
| Dec 2022 | 236.91M | -89.72M | 13.45M |
|---|---|---|---|
| Mar 2023 | -22.39M | -153.04M | 145.86K |
| Jun 2023 | -74.33M | 20.43M | 52.41K |
| Sep 2023 | -28.13M | -7.40M | -152.30K |
POINT Biopharma Global alternative data
| Aug 2023 | 129 |
|---|---|
| Sep 2023 | 129 |
| Oct 2023 | 129 |
| Nov 2023 | 129 |
| Dec 2023 | 129 |
| Jan 2024 | 129 |
| Feb 2024 | 129 |
| Mar 2024 | 129 |
| Apr 2024 | 129 |
| May 2024 | 129 |
| Jun 2024 | 129 |
| Jul 2024 | 129 |
POINT Biopharma Global other data
15.90%
-50.25%
of PNT is owned by hedge funds
62
-45
15.26M
-45.85M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 896366 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BVF PARTNERS L P/IL | Common Stock, $0.0001 par value | 896,366 | $12.45 | $11,159,757 | ||
Option | HOGUE GERALD L. director | Stock Option (Right to Buy) | 17,936 | $6.97 | $125,014 | ||
Option | HOGUE GERALD L. director | Common Stock | 17,936 | $6.97 | $125,014 | ||
Purchase | MCCANN JOE A. director, officer: Chief Execut.. | Common Stock | 2,160 | $6.64 | $14,342 | ||
Purchase | MALIK RAJESH director | Common Stock | 3,700 | $6.66 | $24,642 | ||
Purchase | HOGUE GERALD L. director | Common Stock | 3,660 | $6.82 | $24,943 | ||
Purchase | LUBNER DAVID CHARLES director | Common Stock | 3,600 | $6.85 | $24,660 | ||
Purchase | MARGOLIN YAEL director | Common Stock | 1,710 | $6.56 | $11,218 | ||
Purchase | GOODMAN JONATHAN R. director | Common Stock | 6,000 | $6.33 | $37,980 | ||
Purchase | SILBER ALLAN C director, 10 percent owner, off.. | Common Stock | 22,397 | $6.5 | $145,581 |
Eli Lilly's Big Win In The Obesity Space Just Got Bigger
Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover
POINT Biopharma: Leading The Future Of Radioligand Therapy
POINT Biopharma: Stock Has Upcoming Catalysts With 2 Therapies In Phase 3 Trials
POINT Biopharma: Navigating The Radioligand Therapy Landscape With Strong Financials
Point Biopharma: Interesting, Novel Radiotherapy Developer
Lantheus: Sell Thesis Missing These Key Factors
-
When is POINT Biopharma Global's next earnings date?
Unfortunately, POINT Biopharma Global's (PNT) next earnings date is currently unknown.
-
Does POINT Biopharma Global pay dividends?
No, POINT Biopharma Global does not pay dividends.
-
How much money does POINT Biopharma Global make?
POINT Biopharma Global has a market capitalization of 1.33B.
-
What is POINT Biopharma Global's stock symbol?
POINT Biopharma Global Inc. is traded on the NASDAQ under the ticker symbol "PNT".
-
What is POINT Biopharma Global's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of POINT Biopharma Global?
Shares of POINT Biopharma Global can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does POINT Biopharma Global have?
As Jul 2024, POINT Biopharma Global employs 129 workers.
-
When POINT Biopharma Global went public?
POINT Biopharma Global Inc. is publicly traded company for more then 5 years since IPO on 8 Jul 2020.
-
What is POINT Biopharma Global's official website?
The official website for POINT Biopharma Global is pointbiopharma.com.
-
Where are POINT Biopharma Global's headquarters?
POINT Biopharma Global is headquartered at 4850 West 78th Street, Indianapolis, IN.
-
How can i contact POINT Biopharma Global?
POINT Biopharma Global's mailing address is 4850 West 78th Street, Indianapolis, IN and company can be reached via phone at +64 7 812 2417.
POINT Biopharma Global company profile:
POINT Biopharma Global Inc.
pointbiopharma.comExchange:
NASDAQ
Full time employees:
129
Industry:
Biotechnology
Sector:
Healthcare
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
4850 West 78th Street
Indianapolis, IN 46268
Indianapolis, IN 46268
CIK: 0001811764
ISIN: US7305411099
CUSIP: 730541109
